Partnership Forum: The Academy of Managed Care Pharmacy (AMCP) held a Partnership Forum “Managing Care In The Wave of Precision Medicine” on Dec. 7 and 8 outside of Washington, D.C. More than 30 experts from across the country discussed challenges and provide recommendations to facilitate broader adoption and use of precision medicine across health care settings. AMCP will use the results of this event to inform future strategic initiatives and advocacy efforts.
Press Release: The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) is pleased to announce that Charles Barr, M.D., MPH, has been appointed Chief Science Officer (CSO).
AMCP CEO Blog: The Academy will soon unveil a new strategic plan to guide our organization over the next several years. As it’s rolled out ‒ more on that next month ‒ I thought I would highlight some of the deliberations that went into developing the plan.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the proposed rule Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2019 (CMS-9930-P).
Press Release: Thought leaders representing managed care organizations, providers, patients, biopharmaceutical manufacturers and other stakeholders gathered recently to find solutions to the financial burden of oncology care on patients, while also improving cancer treatment outcomes and advancing the concept of value-based health care.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS), the Centers for Medicare and Medicaid Services (CMS), and the Center for Medicare and Medicaid Innovation (CMMI) for the opportunity to provide comments in response to the request for information (RFI) titled “Centers for Medicare & Medicaid Services: Innovation Center New Direction” released on September 20, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for information titled “Content of Risk Information in the Major Statement in Prescription Drug Direct-to-Consumer Broadcast Advertisements [Docket No. FDA-2017-N-2936]” as published in the Federal Register on August 21, 2017.